Analytical Lens: Exploring Moderna Inc (MRNA)’s Financial Story Through Ratios

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The closing price of Moderna Inc (NASDAQ: MRNA) was $118.32 for the day, up 2.04% from the previous closing price of $115.95. In other words, the price has increased by $2.04 from its previous closing price. On the day, 3.06 million shares were traded. MRNA stock price reached its highest trading level at $118.84 during the session, while it also had its lowest trading level at $115.7.


Our analysis of MRNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.91 and its Current Ratio is at 4.03. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, HSBC Securities on February 26, 2024, Downgraded its rating to Reduce and sets its target price to $86 from $75 previously.

On January 02, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $142.

On November 29, 2023, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $82.Canaccord Genuity initiated its Hold rating on November 29, 2023, with a $82 target price.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 26 ’24 when AFEYAN NOUBAR sold 15,000 shares for $127.22 per share. The transaction valued at 1,908,293 led to the insider holds 2,284,015 shares of the business.

AFEYAN NOUBAR sold 15,000 shares of MRNA for $2,003,561 on Jun 18 ’24. The Director now owns 2,299,015 shares after completing the transaction at $133.57 per share. On Jun 17 ’24, another insider, Hoge Stephen, who serves as the President of the company, sold 15,000 shares for $138.16 each. As a result, the insider received 2,072,400 and left with 1,457,089 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 45344956416 and an Enterprise Value of 38058926080. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.81 while its Price-to-Book (P/B) ratio in mrq is 3.54. Its current Enterprise Value per Revenue stands at 7.386 whereas that against EBITDA is -8.346.

Stock Price History:

The Beta on a monthly basis for MRNA is 1.66, which has changed by -0.03875214 over the last 52 weeks, in comparison to a change of 0.26253593 over the same period for the S&P500. Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $62.55. The 50-Day Moving Average of the stock is -11.05%, while the 200-Day Moving Average is calculated to be 13.86%.

Shares Statistics:

MRNA traded an average of 3.98M shares per day over the past three months and 4062740 shares per day over the past ten days. A total of 382.00M shares are outstanding, with a floating share count of 336.71M. Insiders hold about 12.14% of the company’s shares, while institutions hold 67.27% stake in the company. Shares short for MRNA as of 1718323200 were 21604553 with a Short Ratio of 5.42, compared to 1715731200 on 21430188. Therefore, it implies a Short% of Shares Outstanding of 21604553 and a Short% of Float of 7.4200004.

Earnings Estimates

The firm’s stock currently is rated by 16.0 analysts. On average, analysts expect EPS of -$3.12 for the current quarter, with a high estimate of -$2.67 and a low estimate of -$3.87, while EPS last year was -$3.62. The consensus estimate for the next quarter is -$1.09, with high estimates of -$0.16 and low estimates of -$2.97.

Analysts are recommending an EPS of between -$5.58 and -$7.85 for the fiscal current year, implying an average EPS of -$6.62. EPS for the following year is -$4.95, with 23.0 analysts recommending between -$0.91 and -$6.62.

Revenue Estimates

It is expected that $90B in revenue will be generated in the current quarter, according to 15 analysts. It ranges from a high estimate of $211.88M to a low estimate of $71.85M. As of the current estimate, Moderna Inc’s year-ago sales were $344MFor the next quarter, 15 analysts are estimating revenue of $1.37B. There is a high estimate of $1.83B for the next quarter, whereas the lowest estimate is $379.81M.

A total of 23 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $4.29B, while the lowest revenue estimate was $3.31B, resulting in an average revenue estimate of $3.82B. In the same quarter a year ago, actual revenue was $6.85BBased on 22 analysts’ estimates, the company’s revenue will be $4.33B in the next fiscal year. The high estimate is $5.41B and the low estimate is $3.3B.

Most Popular